CombiGene was granted 3,3 million euro in the latest Phase 2 round in the Horizon 2020 SME Instrument programme. GAEU Consulting assisted with the EU application procedure.
The aim of the project is development and commercialisation of the company’s gene therapy project focusing on difficult-to-treat epilepsy.
Mr. Jan Nilsson, CEO, CombiGene:
“GAEU has contributed to the successful outcome of the Horizon 2020 application. Their experience of the complex application procedure and the hands-on support that we got throughout the entire process were very valuable.”
Mr. Tomasz Wasik, head of GAEU Horizon 2020 Centre of Excellence:
“Our formula is to put together a tailor-made team of experts with high commercial and academic acumen. The application is being produced in good partnerships with our customers. We only use our own personnel.”